Carregant...
PATH-08. CHALLENGES IN OPTIMIZATION OF MGMT PROMOTER METHYLATION ASSAYS FOR DEVELOPMENT OF COMPANION DIAGNOSIS IN GLIOBLASTOMA
BACKGROUNDS: Despite recent limelight of precision medicine in oncology, effective targeted drugs and diagnostics for molecular markers have not been developed or approved for glioblastoma (GBM) yet. Notably, there remain multiple issues in MGMT testing, including determination of optimal assays and...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6847082/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.604 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|